GH Research/$GHRS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Ticker
$GHRS
Sector
Primary listing
Employees
50
Headquarters
Dublin, Ireland
Website
GH Research Metrics
BasicAdvanced
$888M
-
-$0.73
0.97
-
Price and volume
Market cap
$888M
Beta
0.97
52-week high
$20.50
52-week low
$6.72
Average daily volume
338K
Financial strength
Current ratio
29.488
Quick ratio
29.253
Long term debt to equity
0.093
Total debt to equity
0.213
Interest coverage (TTM)
-74.42%
Profitability
EBITDA (TTM)
-52.92
Management effectiveness
Return on assets (TTM)
-12.73%
Return on equity (TTM)
-16.35%
Valuation
Price to book
2.93
Price to tangible book (TTM)
2.93
Price to free cash flow (TTM)
-19.869
Free cash flow yield (TTM)
-5.03%
Free cash flow per share (TTM)
-0.721
Growth
Earnings per share change (TTM)
8.92%
3-year earnings per share growth (CAGR)
49.73%
What the Analysts think about GH Research
Analyst ratings (Buy, Hold, Sell) for GH Research stock.
Bulls say / Bears say
GH Research submitted its complete response to the FDA clinical hold for GH001 ahead of schedule in June 2025, reflecting strong regulatory engagement and possibly accelerating trial timelines (GlobeNewswire).
The Phase 2b GH001-TRD-201 trial achieved its primary endpoint with a highly significant 15.5-point placebo-adjusted reduction in MADRS score at Day 8 (p<0.0001), showing robust efficacy in treatment-resistant depression (Nasdaq).
Cash, cash equivalents, and marketable securities rose to $315.3 million as of March 31, 2025, providing considerable resources to support late-stage development and pivotal trials (GlobeNewswire).
The FDA’s clinical hold on the IND for GH001 remains unresolved, introducing regulatory uncertainty and potential delays for U.S. clinical development (GlobeNewswire).
Net loss increased to $10.8 million in Q1 2025 (from $7.7 million in Q1 2024), reflecting rising administrative expenses that may put future capital under pressure (GlobeNewswire).
GH002, the company’s intravenous mebufotenin candidate, is still in Phase 1 with an IND submission expected in Q4 2025, pushing out pipeline diversification and long-term value creation (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
GH Research Financial Performance
Revenues and expenses
GH Research Earnings Performance
Company profitability
GH Research News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GH Research stock?
GH Research (GHRS) has a market cap of $888M as of November 03, 2025.
What is the P/E ratio for GH Research stock?
The price to earnings (P/E) ratio for GH Research (GHRS) stock is 0 as of November 03, 2025.
Does GH Research stock pay dividends?
No, GH Research (GHRS) stock does not pay dividends to its shareholders as of November 03, 2025.
When is the next GH Research dividend payment date?
GH Research (GHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for GH Research?
GH Research (GHRS) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.